Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Research Council grant · Running

AdrenalWeakness Concomitant Reversal of Adrenal Insufficiency and Muscle Weakness to Enhance Recovery from Prolonged Critical Illness

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 October 2024 to 30 September 2029
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101133276

What the project is doing

In the project's own words, from its summary on CORDIS.

Sepsis, complicated surgery or extensive trauma cause hyperinflammation-induced critical illness which requires vital organ support in an intensive care unit (ICU) in order to avoid imminent death. Although modern intensive care has reduced mortality, a large number of survivors continue to require such supportive care in the ICU sometimes for weeks or months. Once in this prolonged phase, typical ICU-acquired morbidities such as lingering organ failure, muscle wasting and weakness and vasopressor- and ventilator-dependency become the main drivers of poor short- and long-term outcome irrespective of the initial diagnosis upon admission.

Research from our group has focused on two of these unresolved problems, namely ICU-acquired muscle weakness and ICU-acquired adrenal insufficiency, for which there is either no treatment or treatment has deleterious off-target effects that may fuel a vicious circle impairing short- and long-term recovery. Today, intensivists see these conditions as two separate pathophysiological entities, an assumption we think is false.

We hypothesize that ICU-acquired adrenal insufficiency shares upstream underlying mechanisms with ICU-acquired muscle weakness, pathways that are currently unexplored and that can be manipulated with the potential to reverse both problems together. We will test this hypothesis via an experimental and a clinical track. The proposal starts from a novel, controversial idea, developed via experiments in a unique, clinically relevant and validated mouse model of sepsis-induced critical illness and via the study of human patients, and aims to close the loop with a proof-of-concept randomized controlled trial.

Our ambition is to identify and test a novel compound, or combination of compounds, to concomitantly reverse adrenal insufficiency and muscle weakness in prolonged critical illness, while avoiding deleterious side-effects and aiming for synergy. Reaching this ambitious goal would represent ground-breaking progress.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI